Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2018

May 15, 2018

SELL
$18.89 - $32.46 $2.42 Million - $4.15 Million
-127,967 Closed
0 $0
Q4 2017

Feb 14, 2018

SELL
$16.19 - $20.3 $1.81 Million - $2.27 Million
-111,700 Reduced 46.61%
127,967 $2.43 Million
Q3 2017

Nov 14, 2017

BUY
$15.52 - $18.94 $3.72 Million - $4.54 Million
239,667
239,667 $4.43 Million

Others Institutions Holding MGNX

About MACROGENICS INC


  • Ticker MGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,458,800
  • Market Cap $200M
  • Description
  • MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...
More about MGNX
Track Julian Robertson's Portfolio

Track Julian Robertson Portfolio

Follow Julian Robertson (Tiger Management L.L.C.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tiger Management L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Tiger Management L.L.C. and Julian Robertson with notifications on news.